RESEARCH ARTICLE

Antifungal Susceptibilities of Bloodstream Isolates of Candida Species from Nine Hospitals in Korea: Application of New Antifungal Breakpoints and Relationship to Antifungal Usage

Eun Jeong Won1, Jong Hee Shin1*, Min Ji Choi1, Wee Gyo Lee2, Yeon-Joon Park3, Young Uh4, Shine-Young Kim5, Mi-Kyung Lee6, Soo Hyun Kim1, Myung Geun Shin1, Soon Pal Suh1, Dong Wook Ryang1

1 Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea, 2 Department of Laboratory Medicine, Ajou University School of Medicine, Suwon, Republic of Korea, 3 Department of Laboratory Medicine, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea, 4 Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea, 5 Department of Laboratory Medicine, Pusan National University Hospital, Busan, Republic of Korea, 6 Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea

* shinjh@chonnam.ac.kr

Abstract

We applied the new clinical breakpoints (CBPs) of the Clinical and Laboratory Standards Institute (CLSI) to a multicenter study to determine the antifungal susceptibility of bloodstream infection (BSI) isolates of Candida species in Korea, and determined the relationship between the frequency of antifungal-resistant Candida BSI isolates and antifungal use at hospitals. Four hundred and fifty BSI isolates of Candida species were collected over a 1-year period in 2011 from nine hospitals. The susceptibilities of the isolates to four antifungal agents were determined using the CLSI M27 broth microdilution method. By applying the species-specific CBPs, non-susceptibility to fluconazole was found in 16.4% (70/428) of isolates, comprising 2.6% resistant and 13.8% susceptible-dose dependent isolates. However, non-susceptibility to voriconazole, caspofungin, or micafungin was found in 0% (0/370), 0% (0/437), or 0.5% (2/437) of the Candida BSI isolates, respectively. Of the 450 isolates, 72 (16.0%) showed decreased susceptibility to fluconazole [minimum inhibitory concentration (MIC) ≥4 μg/ml]. The total usage of systemic antifungals varied considerably among the hospitals, ranging from 190.0 to 7.7 defined daily dose per 1,000 patient days, and fluconazole was the most commonly prescribed agent (46.3%). By Spearman’s correlation analysis, fluconazole usage did not show a significant correlation with the percentage of fluconazole resistant isolates at hospitals. However, fluconazole usage was significantly correlated with the percentage of fluconazole non-susceptible isolates (r = 0.733; P = 0.025) or the percentage of isolates with decreased susceptibility to fluconazole (MIC ≥4 μg/ml) (r = 0.700; P = 0.036) at hospitals.

Our work represents the first South Korean multicenter study demonstrating an association
between antifungal use and antifungal resistance among BSI isolates of Candida at hospitals using the new CBPs of the CLSI.

Introduction
The incidence of Candida bloodstream infections (BSIs) has increased over the past several decades, and antifungal use has increased drastically worldwide [1, 2]. Although Candida albicans remains the leading Candida species that causes BSI, a shift in the epidemiology of Candida BSI toward greater isolation of non-albicans Candida species has been a global concern in the past two decades [1, 3]. Several studies have evaluated the relationship between antifungal drug use and changes in the epidemiology of candidemia [4–6]; however, to date, few multicenter surveillance studies have been conducted on the relationship between antifungal drug use and the frequency of antifungal resistance of Candida BSI isolates at hospitals. Moreover, several surveillance programs on Candida isolates responsible for BSI worldwide have not reported alterations in the patterns of susceptibility to the azoles or echinocandins over time [1, 3, 5, 6]. The cause may be the rarity of acquired antifungal resistance among BSI Candida isolates or due to the antifungal susceptibility tests and breakpoints being non-optimal for the detection of resistance in Candida isolates [7].

The Clinical and Laboratory Standards Institute (CLSI) recently developed new Candida species-specific clinical breakpoints (CBPs) for fluconazole, voriconazole, and echinocandins [7, 8]. A recent report has shown that resistance to the azoles and echinocandins of Candida species may be increased using the new CLSI CBPs [9]. Therefore, the new CBPs of the CLSI may be applied to antifungal surveillance studies as sensitive tools for detecting emerging resistance in Candida BSI isolates. In the present study, we applied new species-specific CLSI CBPs in a multicenter study to determine the antifungal susceptibility of BSI isolates of Candida species in Korea, and investigated the relationship between the frequency of antifungal resistance of Candida BSI isolates and antifungal use at nine hospitals.

Materials and Methods
A surveillance study was conducted at nine university hospitals (A-I) located throughout Korea to determine the frequency of antifungal resistance of Candida BSI isolates, and to determine their relationship with antifungal use. The participant hospitals were as follows: Ajou University School of Medicine, Suwon; The Catholic University College of Medicine, Seoul; Chonnam National University Hwasun Hospital, Hwasun; Chonnam National University Hospital, Gwangju; Chonbuk National University of Medicine, Jeonju; Chung-Ang University College of Medicine, Seoul; Pusan National University Yangsan Hospital, Yangsan; Yonsei University College of Medicine, Seoul; and Yonsei University Wonju College of Medicine, Wonju. Among the nine hospitals, six had more than 1,000 beds, while the other three (B, D, and I) had 500–1,000 beds. During the 1-year period from January to December 2011, each participant hospital was required to collect blood isolates (one isolate per patient) of Candida species. The annual usage of systemic antifungal agents for patients admitted to each hospital between January and December 2011 was determined by calculating the number of defined daily doses per 1,000 patient days (DDD/1,000 PD), as specified by the WHO ATC/DDD system (www.whocc.no/atcddd/) and the DDD measurement methodology [10]. In addition, the incidence of candidemia was defined as the number of cases of candidemia per 10,000 patient days (PD).
Species identification and antifungal susceptibility testing were performed at Chonnam National University Hospital for all 450 isolates. This study was approved by the institutional review board of Chonnam National University Hospital (IRB CNUH-2011-026). A waiver of consent was granted given the observational nature of the project. The study involved only the results of the species identification and antifungal susceptibility testing of Candida species isolated from routine cultures in the mycology laboratory, and no information was used that could lead to patient identification. Species identification was based on colony morphology using CHROMagar Candida and a commercial system (API 20C; bioMérieux, Marcy L’Étoile, France) (Vitek 2 system; Vitek 2 YST; bioMérieux) or sequencing [11]. Susceptibility to fluconazole, voriconazole, caspofungin, and micafungin was assessed by the CLSI BMD method M27-A3 after 24 h and using the new CLSI-developed CBPs [8, 12]. Revised CLSI CBPs were applied to 437 isolates of six Candida species, including Candida albicans, Candida parapsilosis, Candida tropicalis, Candida glabrata, Candida guilliermondii and Candida krusei, for both caspofungin, and micafungin, while the revised CLSI CBPs were applied to 370 isolates of four common species (C. albicans, C. parapsilosis, C. tropicalis, and C. krusei) for voriconazole. Revised CLSI CBPs for fluconazole were applied to four common Candida isolates (C. albicans, C. parapsilosis, C. tropicalis, and C. glabrata), and all C. krusei isolates are considered resistant to fluconazole irrespective of the minimum inhibitory concentration (MIC) [8]. Two reference strains, C. parapsilosis ATCC 22019 and C. krusei ATCC 6258, were included in each test as quality control isolates. The relationship between antifungal (total or individual) usage and the incidence of candidemia or antifungal susceptibility was determined using Spearman’s rank correlation coefficient (rho, r) and its corresponding P value. A P value less than 0.05 was deemed to indicate significance in both analyses.

Results and Discussion

Table 1 summarizes the in vitro susceptibility of 450 Candida isolates to azoles (fluconazole, voriconazole) and echinocandins (caspofungin and micafungin). Of the 450 total BSI isolates from nine hospitals, 16.0% (72/450) had fluconazole MICs ≥4 μg/mL. By applying the species-specific new CBPs, resistance and susceptible-dose dependence to fluconazole were found in 2.6% (11/428) and 13.8% (59/428) of four common Candida species and C. krusei, respectively. However, no voriconazole, caspofungin or micafungin resistance was detected in any species, with the exception of only two C. parapsilosis isolates which exhibited intermediate resistance (MIC, 4 μg/mL) to micafungin. Overall, Candida BSI isolates remained largely susceptible to the three antifungals, with susceptibility rates of 100%, 100%, and 99.5% for voriconazole, caspofungin, and micafungin, respectively. These findings indicate that the current rate of resistance to voriconazole and two echinocandins among Candida species is low in Korea; this trend is similar to our previous report [13]. However, susceptibility to fluconazole was found in 83.6% (358/428) of the isolates by the new CBPs, which is significantly lower than our previous report (96.4% susceptible, P < 0.005) based on the original CBPs [13].

Several global surveillance programs have demonstrated that most BSIs caused by three common Candida species (i.e., C. albicans, C. tropicalis, and C. parapsilosis) are susceptible to fluconazole using the original CLSI CBPs [3, 13]. During the past few years, the CLSI has adjusted CBPs for fluconazole by lowering them to the same MIC values (S, ≤2 μg/mL; susceptible dose dependent [SDD], 4 μg/mL; R, ≥8 μg/mL) as the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for three common Candida species [14]. Using these species-specific CBPs, trends toward increased resistance to fluconazole in these three species were noted [9, 15]. Similarly, 2.2% (8/366) of isolates of three common Candida species in the present study were categorized as fluconazole non-susceptible (resistant or SDD) based on the
revised CLSI CBPs, while none were categorized as fluconazole non-susceptible based on the original CBPs (fluconazole MIC, ≥16 μg/ml). Additionally, only 34.5% (20/58) of C. glabrata were categorized as fluconazole non-susceptible (10.3% resistant or 24.1% SDD) based on the original CBPs, but all 58 isolates of C. glabrata were categorized as fluconazole non-susceptible (10.3% resistant and 89.7% SDD), suggesting that all C. glabrata isolates were no
longer considered susceptible to fluconazole using revised CBPs [7, 8, 14]. In 2013, the EUCAST also defined fluconazole CBPs for C. glabrata (intermediate, 0.002 to 32 μg/ml; resistant, >32 μg/ml; [http://www.eucast.org/clinical_breakpoints/; version 7.0]), suggesting that a harmonization of CBPs between the CLSI and the EUCAST for fluconazole has been achieved for the four most common Candida species [14, 16]. Overall, these data show that non-susceptibility to fluconazole of Candida species may be increased using the new CLSI CBPs, which may thus be a sensitive measure for detecting the emergence of Candida strains with decreased fluconazole susceptibility, a finding that is consistent with other reports [7, 9].

The incidence of candidemia, antifungal agent consumption, and the percentage of fluconazole non-susceptible Candida BSI isolates at nine Korean hospitals are shown in Table 2. The average incidence of candidemia at the nine university hospitals was 2.01 (1.14 to 2.70) per 10,000 PD. The most prevalent species was C. albicans (average: 0.79 episodes/10,000 PD; 40.4%) followed by C. parapsilosis (19.9%), C. tropicalis (17.6%), and C. glabrata (14.2%). There was considerable variation in total antifungal use at the nine hospitals, ranging from 7.7 to 190.0 DDD/1,000 PD. Fluconazole was the most common agent (average: 29.3 DDD/1,000 PD; 46.3%), followed by itraconazole (20.5%), amphotericin B (13.6%), voriconazole (7.4%), lipid formulation of amphotericin B (7.3%), and the echinocandins (4.9%). Oral fluconazole represented 77.5% of the total fluconazole usage at the nine hospitals (36.0% of the total antifungal usage). The mean total usage of antifungals was 63.2 DDD/PD, which was higher than that in 2005 (39.2 DDD/PD) [17]. In addition, the mean usage of fluconazole more than doubled from 2005 (11.7 DDD/1,000PD) to 2011 (29.3 DDD/1,000 PD) [17]. Accordingly, the rate of fluconazole resistance (MIC ≥64 μg/ml) of C. glabrata was increased to 10.3% (6/58) in the present study (2011), compared with 6% (2/72) in our previous multicenter study (2006–2007) [13].

The use of fluconazole has been suggested to be associated with an increased risk of candidemia caused by non-albicans Candida species [4, 18]. However, serial follow-up studies demonstrated that antifungal usage increased significantly, but the incidence of non-albicans candidemia was maintained [5, 6]. In the present study, no relationship was found between antifungal use and the incidence of candidemia caused by all non-albicans Candida or all Candida species. However, the incidence of candidemia caused by all Candida species other than three common species showed positive correlations with usage of total (oral and intravenous) fluconazole ($r = 0.681, P = 0.044$) or oral fluconazole ($r = 0.773, P = 0.015$). In addition, oral fluconazole usage showed a significant positive correlation with the incidence of candidemia caused by C. glabrata ($r = 0.832, P = 0.005$). This is supported by the report that the most of C. albicans, C. tropicalis, and C. parapsilosis are highly susceptible to fluconazole, but many of the less common Candida species, including C. glabrata, exhibit decreased susceptibility to fluconazole [19].

When the species-specific new CBPs were applied, the percentage of fluconazole non-susceptible Candida BSI isolates varied among the nine hospitals from 5.3% to 33.3% (Table 2). Because revised species-specific CBPs are not at present available for less common Candida species, we also assessed the percentage of decreased susceptibility to fluconazole (MIC ≥4 μg/ml) in all 450 BSI isolates, which also varied among the hospitals from 5.3% to 26.5%. By Spearman’s correlation analysis, total fluconazole usage showed positive correlations with the percentage of isolates with decreased susceptibility to fluconazole (MIC ≥4 μg/ml) ($r = 0.700, P = 0.036$) at hospitals (Fig. 1). Moreover, the incidence of candidemia caused by fluconazole non-susceptible Candida isolates showed positive correlations with usage of total fluconazole ($r = 0.733, P = 0.025$) or oral fluconazole ($r = 0.8, P = 0.01$).
In the present study, we evaluated the annual usage of systemic antifungal agents for patients admitted to each hospital. However, given the fact that many of the hematologic patients are exposed to heavy antifungal use as outpatients, oral fluconazole use for outpatients also may have an influence on the frequency of antifungal-resistant *Candida* BSI isolates at hospitals. Among nine hospitals, the higher use of antifungal agents including fluconazole was found in two hospitals (hospitals A and B) which reported a higher population of

### Table 2. The incidence of candidemia, antifungal drug usage, and fluconazole susceptibility among bloodstream isolates of *Candida* species at nine university hospitals in 2011.

| Parameters | Hospital (Annual patient-days) | Average (%) |
|------------|---------------------------------|-------------|
|            | A (412,959)                     |             |
|            | B (220,761)                     |             |
|            | C (361,580)                     |             |
|            | D (219,562)                     |             |
|            | E (683,220)                     |             |
|            | F (329,957)                     |             |
|            | G (387,335)                     |             |
|            | H (364,687)                     |             |
|            | I (266,017)                     |             |
| Incidence of candidemia episodes/10,000 patient-days | | |
| Three common species | | |
| *C. albicans* | 0.48 | 0.59 | 0.91 | 1.18 | 1.23 | 1.03 | 0.34 | 0.85 | 0.53 | 0.79 (40.4) |
| *C. parapsilosis* | 0.31 | 0.45 | 0.5 | 0.55 | 0.31 | 0.88 | 0.26 | 0.47 | 0.08 | 0.42 (19.9) |
| *C. tropicalis* | 0.22 | 0.27 | 0.3 | 0.18 | 0.48 | 0.45 | 0.34 | 0.44 | 0.38 | 0.34 (17.6) |
| Subtotal | 1.02 | 1.31 | 1.71 | 1.91 | 2.02 | 2.36 | 0.93 | 1.75 | 0.98 | 1.6 (78.0) |
| Other than three common species | | |
| *C. glabrata* | 0.41 | 0.18 | 0.41 | 0.5 | 0.38 | 0.15 | 0.15 | 0.11 | 0.23 | 0.28 (14.2) |
| *C. guilliermondii* | 0 | 0.05 | 0.08 | 0.05 | 0.03 | 0.15 | 0 | 0.05 | 0 | 0.05 (2.1) |
| Others | 0.07 | 0.18 | 0.28 | 0.23 | 0.09 | 0.03 | 0.05 | 0.16 | 0.04 | 0.13 (5.7) |
| Subtotal | 0.48 | 0.41 | 0.77 | 0.77 | 0.5 | 0.33 | 0.21 | 0.33 | 0.26 | 0.45 (22.0) |
| Total, all *Candida* species | 1.5 | 1.72 | 2.49 | 2.69 | 2.52 | 2.7 | 1.14 | 2.08 | 1.24 | 2.01 (100) |
| Usage of antifungal drug, defined daily dose/1,000 patient-days | | |
| Fluconazole, total | 59.8 | 58.4 | 43.7 | 43.2 | 28.4 | 14 | 7.5 | 4.5 | 4.1 | 29.3 (46.3) |
| Oral | 56.6 | 32.1 | 35.5 | 38.3 | 23.6 | 8.6 | 7.5 | 5.0 | 1.8 | 22.7 (36.0) |
| Intravenous | 3.3 | 26.3 | 8.2 | 4.9 | 4.8 | 5.4 | 0.0 | 4.0 | 2.3 | 6.6 (10.4) |
| Itraconazole | 15.7 | 68.8 | 5.3 | 4.3 | 5.5 | 2.1 | 1.9 | 1.6 | 11.5 | 13 (20.5) |
| Amphotericin B | 18.9 | 15.6 | 5.7 | 4.7 | 20.5 | 2.5 | 6.8 | 0 | 2.8 | 8.6 (13.6) |
| Voriconazole | 12.7 | 16.9 | 2.1 | 1.2 | 0.8 | 5.6 | 1.4 | 0.4 | 0.9 | 4.6 (7.4) |
| Lipid formulation of amphotericin B | 16 | 21.6 | 2.3 | 0 | 0 | 0 | 0.4 | 0.7 | 0.6 | 4.6 (7.3) |
| Caspofungin | 5.5 | 5.2 | 0.8 | 0 | 0.6 | 0.5 | 0.4 | 0.4 | 0.7 | 1.6 (2.5) |
| Micafungin | 4.9 | 3.4 | 0.7 | 0.6 | 1.9 | 0 | 0.7 | 0.1 | 1.2 | 1.5 (2.4) |
| Anidulafungin | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 (0.0) |
| Total | 133.4 | 190 | 60.6 | 54 | 57.7 | 24.7 | 19.1 | 7.7 | 21.9 | 63.2 (100) |
| The percentage of isolates (No. with indicated result / total no. tested) by the CLSI-M27A* | | |
| Fluconazole resistant | 12.5 (6/48) | 10.0 (2/20) | 0.0 (0/35) | 0.0 (0/40) | 1.1 (1/94) | 0.0 (0/77) | 0.0 (0/37) | 3.4 (2/58) | 0.0 (0/19) | 2.6 (11/428) |
| Fluconazole non-susceptible | 33.3 (16/48) | 15.0 (3/20) | 22.9 (8/35) | 20.0 (8/40) | 17.0 (16/94) | 7.8 (6/77) | 18.9 (7/37) | 8.6 (5/58) | 5.3 (1/19) | 16.4 (70/450) |
| Fluconazole MIC >4 μg/ml | 26.5 (13/49) | 14.3 (3/21) | 22.2 (8/36) | 13.3 (6/45) | 16.0 (15/94) | 11.9 (10/84) | 20.5 (8/39) | 12.7 (8/63) | 5.3 (1/19) | 16.0 (72/450) |

* The percentage of fluconazole resistant or non-susceptible (resistant or susceptible dose-dependent) isolates by revised CLSI CBPs. Revised CLSI CBPs for fluconazole were applied to four common *Candida* isolates (*C. albicans*, *C. parapsilosis*, *C. tropicalis*, and *C. glabrata*), and all *C. krusei* isolates were considered resistant to fluconazole irrespective of the MIC [8].

b *P* < 0.05, significant relationship between oral fluconazole usage and a given category by Spearman correlation analysis.

c *P* < 0.05, significant relationship between total fluconazole usage and a given category by Spearman correlation analysis.

d The percentage of isolates with decreased susceptibility to fluconazole (MIC >4 μg/ml) in all bloodstream isolates tested.
immunocompromised patients (mainly hematological malignancies). The percentages of fluconazole resistant isolates, as expected, were higher in these two hospitals than those in other hospitals (11.8% vs. 0.8%, $P = 0.001$). However, Spearman’s analysis indicated no significant relationship was found between antifungal usage (total or individual) and the presence of fluconazole-resistant *Candida* species among nine hospitals.

Recent two studies have shown that patients with candidemia due to fluconazole non-susceptible *Candida* species are more likely to have received prior or recent fluconazole therapy [20, 21]. In addition, suboptimal initial dosing of prior fluconazole therapy is associated with candidemia with fluconazole-non susceptible *Candida* species [21]. Although the present study found an association, not causality, we first describe here that hospitals with a higher rate of fluconazole use exhibited a higher incidence of candidemia due to fluconazole non-susceptible *Candida* isolates, using revised CLSI CBPs. We also add evidence on a significant relationship between fluconazole use and the incidence of candidemia caused by all *Candida* species other than three common species. To our knowledge, this work represents the first multicenter study to demonstrate an association between antifungal use and the frequency of antifungal resistance of *Candida* BSI isolates at hospitals.

Changing trends in the epidemiology of candidemia and the emergence of antifungal resistance have affected selection of appropriate antifungal agents [1, 7]. A recent study in a hospital showed that an increase in the use of echinocandins was associated with a decrease in the incidence of *C. parapsilosis* or *C. guilliermondii* candidemia and an increase in the incidence of *C. tropicalis* candidemia [4]. However, our data suggested no relationship between the usage of echinocandins and the incidence of candidemia. This might be due to the limited use of echinocandins in Korean hospitals. At present, fluconazole as a commonly used antifungal agent is
suggested to contribute to the changing epidemiology of candidemia at Korean hospitals. However, given the increasing use of antifungal drugs, including echinocandins, continuous national surveillance programs using the new antifungal CBPs are needed to identify changes in the antifungal susceptibility patterns of Candida BSI isolates.

Author Contributions
Conceived and designed the experiments: JHS. Performed the experiments: JHS EJW MJC. Analyzed the data: JHS EJW WGL YJP YU SYK MKL SHK. Contributed reagents/materials/analysis tools: JHS WGL YJP YU SYK MKL SHK. Wrote the paper: JHS EJW MGS SPS DWR.

References
1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20: 133–163. PMID: 17223626
2. Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013; 19: e343–353. doi: 10.1111/1469-0691.12112 PMID: 23607326
3. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. 2011; 49: 396–399. doi: 10.1128/JCM.01398-10 PMID: 21068282
4. Lai CC, Chu CC, Wang CY, Tsai HY, Cheng A, Lee YC, et al. Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan. Int J Antimicrob Agents. 2012; 40: 349–353. doi: 10.1016/j.ijantimicag.2012.05.024 PMID: 22819796
5. Marcos-Zambrano LJ, Escribano P, Sanchez C, Muñoz P, Bouza E, Guinea J. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother. 2014; 58: 4565–4572. doi: 10.1128/AAC.02670-14 PMID: 24867799
6. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. J Clin Microbiol. 2013; 51: 841–848. doi: 10.1128/JCM.00266-12 PMID: 23269738
7. Pfaffer MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012; 50: 2846–2856. doi: 10.1128/JCM.00937-12 PMID: 22740712
8. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth Informational Supplement. M27-S4. 2012. CLSI, Wayne, PA.
9. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol. 2014; 52: 994–997. doi: 10.1128/JCM.03044-13 PMID: 24403302
10. Merlo J, Wessling A, Melander A. Comparison of dose standard units for drug utilisation studies. Eur J Clin Pharmacol. 1996; 50: 27–30. PMID: 8739807
11. Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009; 48: e57–61. doi: 10.1086/597108 PMID: 19193113
12. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved Standard, 3rd edn, M27-A3. 2008. CLSI, Wayne, PA.
13. Jung SI, Shin JH, Song JH, Peck KR, Lee K, Kim MN, et al. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol. 2010; 48: 669–674. doi: 10.3109/13693780903410386 PMID: 20392145
14. Pfaffer MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D; CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010; 13: 180–195. doi: 10.1016/j.drup.2010.09.002 PMID: 21050800
15. Jang MJ, Shin JH, Lee WG, Kim MN, Lee K, Lee HS, et al. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values. Ann Lab Med. 2013; 33: 167–173. doi: 10.3343/aim.2013.33.3.167 PMID: 23667842
16. Pfaffer MA, Castanheira M, Messer SA, Rhomberg PR, Jones RN. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. Diagn Microbiol Infect Dis. 2014; 79: 198–204. doi:10.1016/j.diagmicrobio.2014.03.004 PMID: 24736096

17. Kim SH, Shin JH, Kim EC, Lee K, Kim MN, Lee WG, et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol. 2009; 47: 296–304. doi:10.1080/13693780802291445 PMID: 18668423

18. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008; 46: 1206–1213. doi:10.1086/529435 PMID: 18444857

19. Pfaffer MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro susceptibilities of rare Candida blood stream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis. 2004; 48: 101–105. PMID: 14972378

20. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011; 55: 532–538. doi:10.1128/AAC.01128-10 PMID: 21078946

21. Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012; 56: 3239–3243. doi:10.1128/AAC.00019-12 PMID: 22411611